QUELL

Quell Therapeutics Limited

Application Filed: 2019-04-04
Trademark Application Details
Trademark Logo QUELL

Mark For: QUELL® trademark registration is intended to cover the categories of pharmaceutical and biological preparations for diagnostic, medical, therapeutic, and prophylactic use for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; veterinary preparations for diagnostic, medical, therapeutic, and prophylactic use for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for cell therapy, namely, preparations comprising T cells having an immunosuppressive phenotype; preparations for gene therapy; pharmaceutical, medical, and clinical preparations for use in treatment, amelioration and prophylaxis of immune system related diseases and disorders; preparations for therapies to modulate the immune system for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for therapies for autoimmune conditions and immunological disorders; cancer preparations, namely, chimeric antigen receptors and therapeutic preparations thereof for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; diagnostic kits consisting of monoclonal antibodies for use in disease testing and for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for therapeutic delivery of nucleic acids for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; viral or nucleic acid vectors for therapeutic or prophylactic purposes and preparations containing such vectors for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for genetically modifying human and animal cells for diagnostic and medical purposes; preparations of blood or cells extracted from humans or animals which have been adapted for therapeutic purposes; none of the foregoing having any relation to pain treatment or management. [all]

Status

2020-06-21 UTC
LIVE REGISTRATION Issued and Active
The trademark application has been registered with the Office.


Research OneLook Acronym Finder
Serial Number88372290
Registration Number6077717
Mark Literal ElementsQUELL
Mark Drawing Type4 - STANDARD CHARACTER MARK
Mark TypeTRADEMARK. SERVICE MARK
RegisterPRINCIPAL
Current LocationPUBLICATION AND ISSUE SECTION 2020-06-16
Basis44(e)
Class StatusACTIVE
Primary US Classes
  • 006: Chemicals and Chemical Compositions
  • 018: Medicines and Pharmaceutical Preparations
  • 044: Dental, Medical and Surgical Appliances
  • 046: Foods and Ingredients of Foods
  • 051: Cosmetics and Toilet Preparations
  • 052: Detergents and Soaps
Primary International Class
  • 005 - Primary Class
  • (Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed UseNo
Current UseNo
Intent To UseNo
Filed ITUYes
44D FiledYes
44E CurrentYes
66A CurrentNo
Current BasisNo
No BasisNo
Domestic RepresentativeSteven T. Shelton
Attorney NameSteven T. Shelton

Timeline

2019-04-04Application Filed
2019-04-08Location: NEW APPLICATION PROCESSING
2019-04-08Status: Live/Pending
2019-04-08Transaction Date
2020-03-31Published
2020-06-16Location: PUBLICATION AND ISSUE SECTION
2020-06-16Status: Registered. The registration date is used to determine when post-registration maintenance documents are due.
2020-06-16Trademark Registered

Trademark Parties (Applicants & Owners)

Party: Quell Therapeutics Limited
Address2nd Floor, 8 Bloomsbury Street London UNITED KINGDOM WC1B3SR
Legal Entity TypeLimited Company (ltd.)
Legal Entity StateUNITED KINGDOM

Attorney of Record

STEVEN T. SHELTON
SHELTON IP
75 SOUTH BROADWAY, SUITE 400
WHITE PLAINS, NY 10601-4413

Good, Services, and Codes


IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical and biological preparations for diagnostic, medical, therapeutic, and prophylactic use for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; veterinary preparations for diagnostic, medical, therapeutic, and prophylactic use for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for cell therapy, namely, preparations comprising T cells having an immunosuppressive phenotype; preparations for gene therapy; pharmaceutical, medical, and clinical preparations for use in treatment, amelioration and prophylaxis of immune system related diseases and disorders; preparations for therapies to modulate the immune system for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for therapies for autoimmune conditions and immunological disorders; cancer preparations, namely, chimeric antigen receptors and therapeutic preparations thereof for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; diagnostic kits consisting of monoclonal antibodies for use in disease testing and for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for therapeutic delivery of nucleic acids for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; viral or nucleic acid vectors for therapeutic or prophylactic purposes and preparations containing such vectors for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for genetically modifying human and animal cells for diagnostic and medical purposes; preparations of blood or cells extracted from humans or animals which have been adapted for therapeutic purposes; none of the foregoing having any relation to pain treatment or management
IC 040. US 100 103 106. G & S: Manufacturing and processing pharmaceuticals for others; manufacturing and processing biological, biotechnological and biopharmaceutical preparations for others; processing of biological tissue, blood, cell, and genetic material for others; production and manufacture of viral vectors for others; production and manufacture of gene therapy products for others; custom manufacture of pharmaceutical and biological preparations for others; none of the foregoing having any relation to pain treatment or management
IC 042. US 100 101. G & S: advisory services relating to gene therapy and design; Scientific and technological services, namely, research and design in the field of T cells with an immunosuppressive phenotype and transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; industrial analysis and research in the field of cell therapy; medical and veterinary research services in the field of the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of new therapies in the field of autoimmune, immunological disorders and to modulate the immune system; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vectors and preparations for manipulating and adapting human and animal cells; scientific and technological services, namely, design in the field of cell therapy; none of the foregoing having any relation to pain treatment or management
IC 044. US 100 101. G & S: Medical services; medical services in the field of immunology; medical services in the field of surgery; medical services in the field of autoimmune diseases and conditions; medical services, in the field of, tissue transplant surgery; collection and preservation of biological tissue, blood, cells and genetic materials; medical diagnosis of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; Medical treatment of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; providing information and data for diagnosis and medical treatment of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; gene and nucleic acid delivery or modification for therapeutic purposes; medical treatment, namely, administering cell or gene therapies; advisory services in the field of health as it relates to cell or gene therapy; medical advisory services relating to cell or gene therapy; none of the foregoing having any relation to pain treatment or management

International Codes:5
U.S. Codes:006,018,044,046,051,052
International Codes:40
U.S. Codes:100,103,106
International Codes:42
U.S. Codes:100,101
International Codes:44
U.S. Codes:100,101
Type CodeType
GS0051Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use; pharmaceutical, medical and veterinary preparations for diagnostic, therapeutic and prophylactic purposes; preparations for cell therapy; preparations for gene therapy; pharmaceutical, medical and clinical preparations for use in treatment, amelioration or prophylaxis of diseases, disorders or suppression of the immune system; immunological agents and preparations; preparations for therapies to modulate the immune system; preparations for therapies to autoimmune conditions or immunological disorders; chimeric antigen receptors and therapeutic preparations thereof; antibodies; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; preparations for genetically modifying human or animal cells for diagnostic and medical purposes; preparations of blood or cells extracted from humans or animals which have been adapted for therapeutic purposes
GS0051Pharmaceutical and biological preparations for diagnostic, medical, therapeutic, and prophylactic use for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; veterinary preparations for diagnostic, medical, therapeutic, and prophylactic use for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for cell therapy, namely, preparations comprising T cells having an immunosuppressive phenotype; preparations for gene therapy; pharmaceutical, medical, and clinical preparations for use in treatment, amelioration and prophylaxis of immune system related diseases and disorders; preparations for therapies to modulate the immune system for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for therapies for autoimmune conditions and immunological disorders; cancer preparations, namely, chimeric antigen receptors and therapeutic preparations thereof for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; diagnostic kits consisting of monoclonal antibodies for use in disease testing and for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for therapeutic delivery of nucleic acids for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; viral or nucleic acid vectors for therapeutic or prophylactic purposes and preparations containing such vectors for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for genetically modifying human and animal cells for diagnostic and medical purposes; preparations of blood or cells extracted from humans or animals which have been adapted for therapeutic purposes; none of the foregoing having any relation to pain treatment or management

Trademark Filing History

DescriptionDateProceeding Number
REGISTERED-PRINCIPAL REGISTER2020-06-16
PUBLISHED FOR OPPOSITION2020-03-31
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED2020-03-31
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED2020-03-11
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED2020-02-256328
EXAMINERS AMENDMENT E-MAILED2020-02-256328
EXAMINERS AMENDMENT -WRITTEN2020-02-2594639
EXAMINER'S AMENDMENT ENTERED2020-02-2588888
APPROVED FOR PUB - PRINCIPAL REGISTER2020-02-25
TEAS/EMAIL CORRESPONDENCE ENTERED2020-02-1388889
TEAS RESPONSE TO OFFICE ACTION RECEIVED2020-02-13
CORRESPONDENCE RECEIVED IN LAW OFFICE2020-02-1388889
NOTIFICATION OF NON-FINAL ACTION E-MAILED2020-01-236325
NON-FINAL ACTION WRITTEN2020-01-2394639
NON-FINAL ACTION E-MAILED2020-01-236325
TEAS/EMAIL CORRESPONDENCE ENTERED2019-12-3074221
CORRESPONDENCE RECEIVED IN LAW OFFICE2019-12-3074221
ASSIGNED TO LIE2019-12-3074221
TEAS RESPONSE TO OFFICE ACTION RECEIVED2019-12-09
NOTIFICATION OF NON-FINAL ACTION E-MAILED2019-06-246325
NON-FINAL ACTION WRITTEN2019-06-2494639
NON-FINAL ACTION E-MAILED2019-06-246325
ASSIGNED TO EXAMINER2019-06-1494639
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM2019-04-22
NEW APPLICATION ENTERED IN TRAM2019-04-08

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed